Stay updated on Regeneron Press Releases

Sign up to get notified when there's something new on the Regeneron Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Regeneron Press Releases page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    Change Detected
    Summary
    The value on the webpage has changed from Apr 29 EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases to Jun 11 Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA). This change represents the approval of Kevzara for the treatment of active polyarticular juvenile idiopathic arthritis by the FDA.
    Difference
    100%
    Check dated 2024-06-11T21:37:59.000Z thumbnail image
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    13 days ago
    Change Detected
    Summary
    The value 'Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO' has been updated to 'Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD'. This change likely reflects new developments in the approval status and focus of the company's pharmaceutical products.
    Difference
    100%
    Check dated 2024-05-31T14:06:02.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The value on the webpage has changed from highlighting advances in genetic medicine research to reporting promising anti-tumor activity of a novel bispecific antibody in combination with Libtayo at ASCO, indicating a shift in focus towards cancer treatment developments.
    Difference
    100%
    Check dated 2024-05-24T07:37:43.000Z thumbnail image
  8. Check
    24 days ago
    Change Detected
    Summary
    The value on the webpage has changed from Apr 7 Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma to May 20 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine. This change represents a shift in focus from one drug's data presentation to another, highlighting new findings in a different medical context.
    Difference
    100%
    Check dated 2024-05-21T06:52:23.000Z thumbnail image
  9. Check
    27 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 'Apr 1 Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024' to 'May 17 More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024'.
    Difference
    100%
    Check dated 2024-05-18T03:44:53.000Z thumbnail image
  10. Check
    31 days ago
    Change Detected
    Summary
    The webpage value has changed from 'Mar 25 Regeneron Provides Update on Biologics License Application for Odronextamab' to 'May 13 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)'. This represents a significant update in the status of the biologics license application, shifting focus to the priority review of Dupixent for the treatment of adolescents with CRSwNP.
    Difference
    100%
    Check dated 2024-05-13T23:23:36.000Z thumbnail image

Stay in the know with updates to Regeneron Press Releases

Enter your email address, and we'll notify you when there's something new on the Regeneron Press Releases page.